.............................................................................................................................................................3

...................................................................................................4

......................................................................................................................................................5

...............................................................................................................................................6

......................................................................................................................................................7

......................................................................................................................................................8

.................................................................................................................... 8........................................................................................................................ 9

ANALYTIC FRAMEWORK ....................................................................................................... 9......................................................................................................................................... 10

............................................................................................ 11.......................................................................................................................... 12

...................................................................................................................... 12......................................................................................................................................... 13

....................................................................................................................................................14

............................................................................................................................. 14

............................................................................................................................. 15 ............................................................................................................................. 15 (PSA) ..................................................................................................... 16

.....................................................................................................................................23

....................................................................................................................................................24

..................................................................................................................................... 24...................................................................................................................... 25...................................................................................................................... 26

.............................................................................................................. 28.................................................................................... 29

......................................................................... 30............................................................................. 31

............................................................................................................................. 32

.............................................................................................................................................34

...........................................................................................................................................................35

3

2-

PSA 1-/2-

PSA

4

Analytic Framework

MEDLINE

DARE HTA

PSA

PSA

PSA

PSA

PSA

PSA

5

6

7

Analytic Framework AF

2

2.

NICE National Institute for Health and Clinical Excellence

CDC(Centers for Disease Control and Prevention)

Community Guide

GRADE

USPSTF(US Preventive Services Task Force) CTFPHC(Canadian Task Force on Preventive Health Care)

2+

2-

8

9

10

11

12

13

1985 1 1 2006

MEDLINE374 DARE43 MEDLINE 2006 10 1

DARE 2006 9 16 ERSPC (European Randomized Study of Screening for Prostate

Cancer) PLCO Prostate, Lung, Colorectal and Ovarian Cancer Trial)

2006 10 1 MEDLINE DARE 145

573

2006 9 19 30

21

2 1 5

52 7

65 7

72 117 14

2

1 44 1

54 25

23 2 67 3

16 19

2

64 1

1

9 2

USPSTF 5

4 2

69 3

33

2 18

81 13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, Graham E, Echols RM,

Whalen E, Kowalsky SF. Single-dose oral ciprofloxacin versus placebo for prophylaxis during

transrectal prostate biopsy. Urology. 1998;52(4):552-558.

Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD.

Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal

examination and prostate specific antigen. J Urol. 2002;167(2 Pt 2):966-975.

Rodrguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle

biopsy: a prospective study and review of the literature. J Urol. 1998;160(6 Pt 1):2115-2120.

Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C,

Marberger M.. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle

biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001;166(3):

856-860.

Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk

factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a

population-based screening program. Urology. 2002;60(5):826-830.

Crawford ED, Haynes AL Jr, Story MW, Borden TA. Prevention of urinary tract infection and sepsis

following transrectal prostatic biopsy. J Urol. 1982;127(3):449-451.

Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a

randomized controlled study. BJU Int. 2000;85(6):682-685.

Norberg M, Holmberg L, Hggman M, Magnusson A. Determinants of complications after multiple

transrectal core biopsies of the prostate. Eur Radiol. 1996;6(4):457-461.

, , , , .

1 2002;93(5):648-651.

, , , , , , , ,

, , . 1 .

. 2002;76(10):893-897.

Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC,

Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate

cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283:354-360.

Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA. The use of

treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer. 2002;95(11):

2397-2407.

Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time

trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA.

1993;269:2633-2636.

Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norln BJ, Holmberg L. Quality of

life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790-796.

40

41

42

43

44